as of 07-17-2026 3:39pm EST
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BREA |
| Market Cap: | 4.2B | IPO Year: | 2019 |
| Target Price: | $26.46 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.23 | EPS Growth: | 104.31 |
| 52 Week Low/High: | $18.77 - $30.42 | Next Earning Date: | 05-06-2026 |
| Revenue: | $2,566,500,000 | Revenue Growth: | -0.10% |
| Revenue Growth (this year): | 6.67% | Revenue Growth (next year): | 3.55% |
| P/E Ratio: | 117.46 | Index: | N/A |
| Free Cash Flow: | 230.4M | FCF Growth: | -23.89% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
SEC 8-K filings with transcript text
May 6, 2026 · 100% conf.
1D
+0.45%
$27.19
5D
-2.61%
$26.36
20D
-5.43%
$25.60
2 nvst-ex991x4326xworkingfil.htm
Document
Exhibit 99.1
Envista Reports First Quarter 2026 Results
BREA, Calif., May 6, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended April 3, 2026.
“We delivered a good start to 2026, with first quarter results reflecting continued strong execution and progress in support of our strategic priorities,” said Paul Keel, CEO. “We delivered growth across all our major businesses, driven by customer engagement and new product commercialization. Our 9.5% core revenue growth converted to 25% adjusted EBITDA and 50% EPS growth, while also supporting double-digit increases in R&D and Sales & Marketing investment. With momentum continuing, we are reaffirming our full-year guidance and announcing an incremental $300 million share repurchase program.”
First Quarter Financial Highlights
•Sales were $706 million, with core sales growth of 9.5% over the first quarter of 2025.
•GAAP diluted EPS of $0.23 and adjusted diluted EPS of $0.36 (+50% year-on-year)
•GAAP Net Income was $39 million and adjusted EBITDA was $99 million (+25% year-on-year), with an adjusted EBITDA margin of 14.0% (+120 bps year-on-year)
First Quarter Business Highlights
•Growth: In the context of macro uncertainty, all major businesses delivered positive growth, with 8.4% core growth in our Specialty Products & Technologies segment and 11.5% core growth in our Equipment and Consumables segment.
•Operations: Ongoing broad-based contributions from the Envista Business System (EBS) supporting 100 bps of Gross Margin and 120 bps of adjusted EBITDA margin expansion.
•People: Continued gains in employee engagement and talent development; 3700 patients served through our charitable Envista Smile Project.
Net Income, EBITDA, and EPS (in millions, except per share amounts):
Three Months Ended
April 3, 2026March 28, 2025
GAAP Net Income$39 $18
Adjusted Net Income$60 $42
Adjusted EBITDA$99 $79
GAAP Diluted Earnings Per Share$0.23 $0.10
Adjusted Diluted Earnings Per Share$0.36 $0.24
Cash Flow:
Operating cash flow for the first quarter of 2026 was negative $3 million and free cash flow was negative $16 million, compared to $0 million and negative $5 million in the first quarter of 2025, respectively.
Share Repurchases:
During the quarter ended April 3, 2026, we repurchased 1.6 million shares for approximately $43 million. At the end of the quarter, we had approximately $41 million remaining repurchase capacity under our stock repurchase program.
On May 5, 2026, our Board of Directors authorized a new stock repurchase program under which we may repurchase an incremental $300 million of our outstanding common stock through December 31, 2029.
Outlook:
We are maintaining the following guidance for the full year 2026:
1
2026 Guidance
Core Sales Growth2% to 4%
Adjusted EBITDA Growth7% to 13%
Adjusted Diluted Earnings Per Share$1.35 to $1.45
Free Cash Conversion~100%
Please note, we do not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated.
We will discuss our quarterly results and provide details on our outlook for 2026 during an investor conference call on May 6, 2026, starting at 2:00 P.M. PT. The call and an accompanying slide presentation will be webcast on the "Investors" section of our website,www.envistaco.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of our website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.
The conference call can be accessed by dialing 800-836-8184 within the U.S. or +1 646-357-8785 outside the U.S. a few minutes before 2:00 PM PT and referencing conference ID #51461. A replay of the conference call will be available shortly after the conclusion of the call. You can access the replay dial-in information on the "Investors" section of our website under the subheading "Events & Presentations." Presentation materials relating to our results have been posted to the "Investors" section of our website under the subheading "Quarterly Earnings".
Envista is a global leader in the dental industry, uniting more than 30 trusted brands—including DEXIS, Kerr, Nobel Biocare, and Ormco—under one mission: partnering with dental professionals to improve patients’ lives. With a heritage of category-defining innovation, our brands have shaped modern dentistry: Nobel Biocare introduced the first dental implant, Ormco is a pioneer in both traditional and digital orthodontics, DEXIS has long been at the forefront of 2D, 3D and intraoral imaging, and Kerr has supported clinicians for over 135 years. Our high-performing culture is underpinned by our CIRCLe Values and the Envista Business System. Guided by these, we deliver a comprehensive portfolio of technologies, consumables, and services tha
Feb 5, 2026 · 100% conf.
1D
+4.90%
$25.92
Act: +17.77%
5D
+5.34%
$26.03
Act: +16.43%
20D
+5.41%
$26.05
Act: +8.92%
nvst-202602050001757073FALSE00017570732026-02-052026-02-05
Washington, D.C. 20549
Date of report (Date of earliest event reported): February 5, 2026
(Exact Name of Registrant as Specified in Its Charter)
Delaware (State or Other Jurisdiction of Incorporation)
001-3905483-2206728 (Commission File Number)(IRS Employer Identification No.)
200 S. Kraemer Blvd., Building E92821 Brea,California (Address of Principal Executive Offices)(Zip Code)
(714) 817-7000 (Registrant’s Telephone Number, Including Area Code) Not applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.01 par value NVST New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On February 5, 2026, Envista Holdings Corporation (“Envista” or the “Company”) issued a press release announcing financial results for the quarter ended December 31, 2025. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. The information contained in the accompanying Exhibit 99.1 is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
The Company intends to reference a slide deck (the “Presentation”) during the Company’s conference call to discuss its financial results for the quarter ended December 31, 2025. A copy of the Presentation can be accessed on the “Investors” section of the Company’s website, www.envistaco.com. The information included or incorporated by reference in this Item 7.01 is being furnished to the SEC and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
(d) Exhibits.
Exhibit No. Description 99.1 Press Release dated February 5, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 5, 2026By:/s/ Eric Hammes Eric Hammes Senior Vice President and Chief Financial Officer (Principal Financial Officer)
Oct 29, 2025
nvst-202510290001757073FALSE00017570732025-10-292025-10-29
Washington, D.C. 20549
Date of report (Date of earliest event reported): October 29, 2025
(Exact Name of Registrant as Specified in Its Charter)
Delaware (State or Other Jurisdiction of Incorporation)
001-3905483-2206728 (Commission File Number)(IRS Employer Identification No.)
200 S. Kraemer Blvd., Building E92821 Brea,California (Address of Principal Executive Offices)(Zip Code)
(714) 817-7000 (Registrant’s Telephone Number, Including Area Code) Not applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.01 par value NVST New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On October 29, 2025, Envista Holdings Corporation (“Envista” or the “Company”) issued a press release announcing financial results for the quarter ended September 26, 2025. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. The information contained in the accompanying Exhibit 99.1 is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
The Company intends to reference a slide deck (the “Presentation”) during the Company’s conference call on October 30, 2025 to discuss its financial results for the quarter ended September 26, 2025. A copy of the Presentation can be accessed on the “Investors” section of the Company’s website, www.envistaco.com. The information included or incorporated by reference in this Item 7.01 is being furnished to the SEC and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
(d) Exhibits.
Exhibit No. Description 99.1 Press Release dated October 29, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 29, 2025By:/s/ Eric Hammes Eric Hammes Senior Vice President and Chief Financial Officer (Principal Financial Officer)
See how NVST stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "NVST Envista Holdings Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.